Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. Amendment No. 2 to Exclusive License and Commercialization AgreementExclusive License and Commercialization Agreement • May 9th, 2024 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2 to the Exclusive License and Commercialization Agreement, as amended (this “Amendment No. 2”), is made and entered into as of March 13, 2024, by and between Shanghai Junshi Biosciences Co., Ltd. (“Junshi”) and Coherus BioSciences, Inc. (“Coherus”). Each of Junshi and Coherus is sometimes referred to herein, individually, as a “Party” and, collectively as the “Parties.”
